Indapamida Tarbis (Indapamide)

Indapamide blocks the sodium‑chloride cotransporter in the distal convoluted tubule of the kidney. This inhibition reduces sodium and water reabsorption, leading to increased urine output, decreased blood volume, and ultimately lower arterial pressure.

The appropriate dose of Indapamida Tarbis is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and renal function. Patients should follow the prescriber’s instructions exactly.

The pregnancy category for indapamide is not definitively established. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant, and after consultation with a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indapamide shares the diuretic class with thiazides but has a longer half‑life and a milder impact on electrolyte balance. It is often preferred when a sustained blood‑pressure reduction is needed with a lower incidence of rapid potassium loss compared with classic thiazides such as hydrochlorothiazide.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep out of reach of children and do not use if the package is damaged or past its expiration date.

Indapamida Tarbis is taken orally, usually with a full glass of water. It may be taken with or without food, but patients should follow the specific instructions given by their prescriber to ensure consistent absorption.

Serious risks include severe dehydration, significant electrolyte disturbances such as hyponatremia or hypokalemia, acute gout attacks, and rare allergic reactions like angioedema. Patients should seek immediate medical attention if they experience symptoms such as rapid weight loss, muscle weakness, severe dizziness, or swelling of the face or throat.

Indapamida Tarbis is contraindicated in individuals with known hypersensitivity to indapamide or other sulfonamide drugs, severe renal impairment, and in patients with anuria. Caution is also advised for those with a history of gout, severe electrolyte abnormalities, or uncontrolled diabetes.